Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01902173

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer

Sponsor: GlaxoSmithKline

Conditions Hematopoietic and Lymphoid Cell Neoplasm Locally Advanced Malignant Solid Neoplasm Locally Advanced Melanoma Metastatic Malignant Solid Neoplasm Metastatic Melanoma Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Malignant Solid Neoplasm Unresectable Melanoma

Interventions Biopsy Biospecimen Collection Computed Tomography Dabrafenib Mesylate Magnetic Resonance Imaging Trametinib Dimethyl Sulfoxide Uprosertib

Updated 25 times since 2017 Last updated: Dec 20, 2024 Started: Oct 8, 2013 Primary completion: May 16, 2018 Completion: Dec 23, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01902173, this PHASE1/PHASE2 trial focuses on Hematopoietic and Lymphoid Cell Neoplasm and Locally Advanced Malignant Solid Neoplasm and remains completed. Sponsored by GlaxoSmithKline, it has been updated 25 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

25 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Dec 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 20 earlier versions

May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2024 — May 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jul 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2021 — Apr 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2021 — May 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Suspended → Active Not Recruiting
Jun 2018 — Nov 2020 [monthly]

Suspended PHASE1_PHASE2
Jun 2017 — Jun 2018 [monthly]

Suspended PHASE1_PHASE2
Feb 2017 — Jun 2017 [monthly]

Suspended PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Suspended PHASE1_PHASE2

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
National Cancer Institute (NCI)
Novartis Pharmaceuticals

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Aurora, United States , Clackamas, United States , Cleveland, United States , Columbus, United States , Los Angeles, United States , Milwaukie, United States , Newberg, United States , Oregon City, United States , Portland, United States and 2 more locations